Keyword: Umer Raffat

Allergan's shares have significantly fallen from their highs in 2015, but now the company is ready to make a big move, one analyst writes.

Analysts pounded the CEOs of BMS and Celgene for details about their integration plans. But investors seemed dissatisfied with their answers.

Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.

Investors panicked in October when Bristol-Myers Squibb said a request for more data from a key lung cancer trial had pushed back an FDA decision.

Key oncology wins helped drive Pfizer and Merck to the top of the Dow in 2018, but the pharma sector faces plenty of hurdles this year.

Among small batch of price increases for the pharma giant was a 1.5% increase on superstar cancer drug Keytruda and 6% on HPV shot Gardasil.

If 2016 was the year immuno-oncology first stopped looking invincible, 2017 was the year trial misses became more commonplace.

If you’re looking for certainty in immuno-oncology, Bristol-Myers’ latest Opdivo-plus-Yervoy data won't help.

The immunotherapy mystery deepens. Merck’s Keytruda missed its goal in a head and neck cancer trial—one its Bristol-Myers rival Opdivo met last year.

The FDA slapped a clinical hold on two Keytruda trials, dashing Merck's hopes of combining the IO star with one of Celgene's big-selling myeloma meds.